Option Care Health Doubles Share Buyback Plan to $1 Billion Amid Positive 2026 Revenue Outlook
Bannockburn, Monday, 12 January 2026.
Option Care Health projects 2026 revenue reaching $6.0 billion and has doubled its share repurchase program to $1.0 billion, signaling robust financial health ahead of tomorrow’s J.P. Morgan Healthcare Conference.
Strategic Outlook and Capital Allocation
Option Care Health (OPCH) has set a confident tone for the coming fiscal year, projecting net revenue between $5.8 billion and $6.0 billion for the full year of 2026 [1][2]. Alongside this top-line growth, the company anticipates adjusted EBITDA to land in the range of $480 million to $505 million [1]. Underscoring its commitment to shareholder returns, the company’s Board of Directors authorized a significant expansion of its share repurchase program on January 9, 2026 [1]. The authorization has been doubled from $500 million to $1.0 billion [1][3]. This move follows a period of active capital allocation, during which Option Care Health repurchased approximately $307 million of its shares throughout 2025 [1][2].
Preliminary 2025 Financial Performance
The preliminary results for the fiscal year ended December 31, 2025, indicate a trajectory of sustained growth. The company expects full-year net revenue to settle between $5.645 billion and $5.655 billion [1]. When compared to the reported net sales of approximately $4.998 billion in 2024, the lower end of this 2025 guidance suggests a year-over-year revenue increase of roughly 12.941 percent [1][4]. For the fourth quarter alone, revenue is anticipated to range from $1.46 billion to $1.47 billion [1].
Profitability and Upcoming Events
In terms of profitability, Option Care Health projects GAAP net income for the full year 2025 to be between $208.2 million and $211.5 million [1][2]. Adjusted EBITDA for the same period is expected to fall within the $469.0 million to $473.0 million band [1]. These figures set the baseline for the company’s 2026 adjusted diluted earnings per share (EPS) projection of $1.82 to $1.92 [2]. While these figures remain preliminary and unaudited, investors can expect further details regarding the full-year 2026 financial guidance during the company’s fourth-quarter earnings call, scheduled for February [2]. In the immediate term, the management team will address the investment community at the J.P. Morgan Healthcare Conference at 10:30 a.m. P.T. on January 13 [1].